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Schizophrenia is a complex psychiatric disorder strongly associated with substance use dis-
orders.Theoretically, schizophrenia and SUD may share endocannabinoid alterations in the
brain reward system.The main endocannabinoids, anandamide, and 2-arachidonoylglycerol,
are lipids which bind cannabinoid receptors. Oleoylethanolamide (OEA), a fatty-acid
ethanolamide, binds peroxisome proliferator-activated receptors.The endocannabinoid sys-
tem has been shown to be impaired in schizophrenia, and recently, our group has shown
that schizophrenia patients with SUD have elevated peripheral levels of anandamide and
OEA that do not normalize after 3-month treatment with quetiapine. Objective For com-
parative purposes, we aimed to measure endocannabinoids in non-psychosis substance
abusers and non-abusing schizophrenia patients. Methods Using liquid chromatography
and mass spectrometry, we measured plasma levels of anandamide and OEA in non-
psychosis SUD patients, non-abusing schizophrenia patients, and healthy controls. In an
open-label manner, all patients received 12-week treatment with quetiapine. Results Anan-
damide and OEA were reduced in substance abusers without schizophrenia, relative to
healthy controls (p<0.05). Both endocannabinoids were unchanged in non-abusing schiz-
ophrenia patients. After quetiapine, anandamide, and OEA levels remained significantly
reduced the SUD group (p<0.05). Discussion Taken together with results of our previous
study performed in dual-diagnosis patients, our results suggest that peripheral anandamide
and OEA levels are impaired in patients with SUD in opposite ways according to the
presence or absence of schizophrenia. Endocannabinoid alterations did not change with
treatment, suggesting that they are trait markers. Further studies are necessary to under-
stand the role of endocannabinoids in substance abusers with and without schizophrenia
and to examine therapeutic implications.
Keywords: schizophrenia, endocannabinoids, anandamide, oleoylethanolamide, substance use disorder, vulnera-
bility marker
INTRODUCTION
Schizophrenia is a complex disease encompassing 0.87% of the
general population (Perala et al., 2007). Psychiatric symptoms and
comorbidities such as substance use disorder (SUD) contribute to
the associated disability. The lifetime prevalence of SUD is approx-
imately 40% in schizophrenia (Regier et al., 1990). It has a negative
impact on drug compliance, psychotic relapses, and on prognosis.
Patients with schizophrenia are more prone to substance abuse
than the general population and 25% have a lifetime prevalence
of cannabis abuse/dependence, the most widely used illicit psy-
choactive substance worldwide (Jablensky, 2000). Cannabinoid
intoxication can provoke cognitive deficits and psychiatric symp-
toms akin to the cognitive and positive symptoms of schizophrenia
(D’Souza et al., 2004). Chronically, cannabis smoking seems to
provoke an amotivational syndrome similar to the negative symp-
toms of the disorder (Nunez and Gurpegui, 2002). Cannabinoid
intoxication has therefore become a valid psychosis model, because
its effects are representative of the full spectrum of schizophre-
nia symptoms. The endogenous cannabinoid (ECB) system may
help to understand the link between schizophrenia and substance
abuse.
The main ECBs, anandamide, and 2-arachidonoylglycerol (2-
AG), are lipids naturally derived from membrane precursors which
bind cannabinoid receptors (CB1, CB2; Ameri, 1999). Although
structurally related to anandamide,palmitoylethanolamide (PEA),
and oleoylethanolamide (OEA) are two non-cannabinoid natural
bioactive fatty-acid ethanolamides (FAEA), as these lipids do not
bind cannabinoids receptors, but bind with high affinity to the
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peroxisome-proliferator-activated receptor- alpha (PPAR-α; Fu
et al., 2003). ECBs are synthesized on request by neurotransmit-
ters and the ECB system is involved in several neuromodulation
processes.
Preliminary evidence suggests that the ECB system is dis-
turbed in schizophrenia (Desfossés et al., 2010). Indeed, post-
mortem human brain studies have shown that CB1 receptor
density is elevated in several brain regions involved in the patho-
physiology of schizophrenia, such as the prefrontal cortex, the
hippocampus, and the basal ganglia (Dean et al., 2001). Simi-
larly, a recent positron emission tomography (PET) study has
brought new insights about the link between schizophrenia and
CB1 receptors. In vivo, it showed an elevation of CB1 recep-
tor binding in patients with schizophrenia across many brain
regions, significantly in the pons, relative to healthy controls
(HC; Wong et al., 2010). CB1 receptor functioning may also be
altered in schizophrenia in brain regions involved in cognition.
Moreover, anandamide levels are increased in the cerebrospinal
fluid (CSF) of patients with schizophrenia compared to healthy
controls (HC) (Leweke et al., 1999) and to individuals with
other psychiatric disorders (Giuffrida et al., 2004). Inconsistently,
anandamide levels have also been shown to be elevated in the
serum of schizophrenia patients (De Marchi et al., 2003), sug-
gesting that anandamide may play a protective role in psychosis
homeostasis.
Theoretically, schizophrenia and SUD may share ECB alter-
ations in the brain reward system. The study of ECB ligands, such
as anandamide and OEA, may provide mechanistic explanations
for the increased vulnerability to SUD in schizophrenia patients
and/or the increased vulnerability to develop psychotic symp-
toms in individuals with SUD. Studies are therefore needed
to explore the role of the ECB system in the pathophysiol-
ogy of schizophrenia which consider the impact of substance
abuse.
A previous study of our group of research examined plasma
endocannabinoid in patients with dual-diagnosis schizophrenia
(Potvin et al., 2008). Plasma anandamide and OEA levels were ele-
vated at baseline in patients compared to controls and were not
modified after 12 weeks of treatment with the second-generation
antipsychotic quetiapine. In the present study, we report plasma
anandamide and OEA concentrations in substance abusers with-
out schizophrenia and in non-abusing schizophrenia patients
assessed in the same clinical conditions and included following
the same criteria as the patients with dual-diagnosis. We exam-
ined endocannabinoid outcomes in substance abusers without
schizophrenia and in non-abusing schizophrenia patients under-
going 12-week treatment with quetiapine. This antipsychotic was
chosen because it has previously been shown to improve sub-
stance use and psychiatric outcomes in psychosis, dual-diagnosis,
and non-psychosis patients (Kampman et al., 2007; Martinotti
et al., 2008; Potvin et al., 2008; Rizkallah et al., 2010). Impor-
tantly, this is the first study of its kind to trace endocannabinoid
outcomes prospectively in these groups. During the trial, we
sought to determine whether: (i) baseline plasma anandamide and
OEA concentrations were different between patients and controls,
(ii) plasma anandamide and OEA levels varied from baseline to
endpoint.
MATERIALS AND METHODS
PARTICIPANTS
To complement the data collected previously in dual-diagnosis
schizophrenia patients and HC (Potvin et al., 2008), three groups
of participants were recruited, namely: (i) non-abusing patients
with schizophrenia-spectrum disorders (schizophrenia, schizoaf-
fective disorder, schizophreniform disorder; SCZ group); (ii) non-
psychotic substance abusers in detoxification (SUD group); and
(iii) a new group of HC. Psychiatric and SUD diagnoses were by
well-trained psychiatrists and physicians, and were all based on
DSM-IV criteria. SUD diagnoses were complemented with urine
drug screenings. All participants signed a detailed consent form.
The study was approved by the local ethics committee.
For all patient groups (SCZ and SUD), exclusion criteria were:
(i) patients already on clozapine or quetiapine; (ii) patients hos-
pitalized in a psychiatric unit; (iii) pregnancy; (iv) female sub-
jects of childbearing potential or inadequate contraception; and
(v) clinically meaningful unstable, renal, hepatic, cardiovascular,
respiratory, cerebro-vascular, or other serious, progressive phys-
ical disease. For the SCZ group, patients were excluded if their
total score on the Positive and Negative Syndrome Scale (PANSS;
Kay et al., 1987) was lower than 65. Importantly, these exclu-
sion criteria are the same as the ones used in our previous
study involving dual-diagnosis patients (Potvin et al., 2008). SUD
patients were diagnosed with one or more of the following SUD:
alcohol (n= 24); cannabis (n= 20); stimulants (n= 15). SCZ
patient received one or more first-generation (n= 5) or second-
generation antipsychotics (n= 14), four patients were drug-free.
For study completers, the mean quetiapine dose was 478.3 mg
(272.0) and 150.0 mg (117.7) in the SCZ and SUD groups, respec-
tively. Of note, in the previous study, dual-diagnosis schizophrenia
patients used similar psychoactive substances, were taking similar
types of antipsychotics and received similar doses of quetiapine
(for more information, see Potvin et al., 2008).
CLINICAL ASSESSMENTS
Psychiatric symptoms were measured using the PANSS and the
Calgary Depression Scale for Schizophrenia (CDSS; Addington
et al., 1993). Quantities of substances used in the last week were
also registered, using the TimeLine Follow-Back (TLFB) procedure
(Sobell et al., 1992). Quantities used were noted for all substances.
Amount spent on substances was calculated based on the value
market in Quebec province (Canada). To complement our eval-
uation of SUD, urine screenings were performed before and after
treatment. SUD severity was also evaluated using the Alcohol Use
and the Drug Use Scales (Drake et al., 1990; for more information,
see Potvin et al., 2008; Rizkallah et al., 2010).
ANALYSIS OF AEA AND OEA FROM PLASMA
We collected blood samples (2 mL) using heparinized tubes.
Within 1 h, blood samples were centrifuged (3200 rpm for 15 min),
and plasma (1 mL) was stored at −80˚C in glass vials. Blood
samples were collected before and after treatment. All extraction
manipulations were done on ice or at 4˚C. Plasma (500µL) was
spiked with 1 ng of internal standard AEA-d8. All samples were
thoroughly vortexed and centrifuged at 15,000 g for 5 min. The
Solid Phase Extraction was conducted according to the method
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developed by Marczylo et al. (2009) with slight modifications. LC-
MS-MS analyses were performed on a Surveyor coupled to a TSQ
Quantum AM Ultra (ThermoFisher, San Jose, CA, USA) operat-
ing in positive electrospray mode. For each analyte, silver adducts
were selected for multiple reaction monitoring (MRM). Injections
of 5µL were done on a 2.6µm Kinetex C18 3.0× 100 mm column
(Phenomenex, Torrance, CA, USA) and separated using a linear
gradient. The eluants consisted of 70µM aqueous silver acetate
(solvent A), 70µM silver acetate in 90% methanol/10% H2O (sol-
vent B), and 70µM silver acetate in 90% acetonitrile/10% H2O
(solvent C). The separation started at 30%A, 20%B, and 50%C and
ended at 0%A, 20%B, and 80%C for a total run time of 20 min.
The lowest limits of quantitation were 0.10 ng/mL for AEA and
0.17 ng/mL for OEA.
STATISTICAL ANALYSES
Baseline differences between SCZ patients, SUD patients and
HC were analyzed using one-way analyses of variance (ANOVA)
with group as the independent variable. Dichotomous variables
were evaluated using Pearson’s chi-square test. Multiple compar-
isons were performed using the Bonferroni correction. Changes
in substance abuse and psychiatric symptoms were analyzed
using repeated-measures ANOVA. Last-observation carried for-
ward (LOCF) was used. The level of significance was set at p< 0.05.
Statistical analyses were performed using the Predictive Analytics
SoftWare (PASW; version 18).
RESULTS
PARTICIPANTS
Twenty-five SCZ patients were prescribed quetiapine; of these, two
were lost-to-follow-up. Thirty-eight SUD patients were recruited,
and 33 SUD patients were prescribed quetiapine; of these, two
were lost-to-follow-up, two dropped out due to side-effects, and
three dropped out due to SUD relapse. Therefore, LOCF analysis
was available for 23 and 26 patients in the SCZ and SUD groups,
respectively.
SOCIO-DEMOGRAPHIC VARIABLES
SCZ patients, SUD patients, and HC did not differ in terms of
age [HC: 37.1 (12.5); SCZ: 40.3 (12.6); SUD: 37.9 (12.1); F = 0.5;
p= 0.626], sex [HC: 16 males (M), 11 females (F); SCZ: 17M, 8F;
SUD: 25M, 13F;χ2= 0.5; p= 0.785], ethnicity (HC: 26 Caucasian;
SCZ: 22 Caucasian; SUD: 34 Caucasian; χ2= 1.3; p= 0.517), and
weight [HC: 76.3 (16.2); SCZ: 76.9 (13.2); SUD: 76.5 (18.0);
F = 0.01; p= 0.992].
SUD OUTCOMES
In SUD patients, all substance use outcomes significantly improved
during treatment (p< 0.05; for more information, see Rizkallah
et al., 2010).
PSYCHIATRIC SYMPTOMS
On baseline, SCZ and SUD patients had similar positive symp-
toms [SCZ: 17.4 (4.4); SUD: 16.2 (5.1); F = 3.2; p= 0.08]; SCZ
patients had more negative symptoms than SUD patients [SCZ:
16.9 (4.7); SUD: 13.6 (4.7); F = 7.2; p= 0.01]; and SUD patients
had more depressive symptoms than SCZ patients [SCZ: 3.6 (4.4);
SUD: 6.8 (4.4); F = 8.4; p= 0.005; Zhornitsky et al., 2011]. In SCZ
and SUD patients, psychiatric symptoms (positive, negative, and
depressive) significantly improved during treatment (p< 0.05; for
more information, see Zhornitsky et al., 2011).
ENDOCANNABINOIDS
Compared to HC, plasma anandamide, and OEA levels were
significantly reduced in SUD patients, but not in SCZ patients
(Table 1). Peripheral anandamide and OEA remained reduced in
the SUD group after quetiapine treatment (Table 2). Noteworthy,
sub-analyses targeting specific psychoactive substances (alcohol,
cannabis, or stimulants) revealed that AEA and OEA levels were
reduced in the SUD group, compared to HC, irrespective of the
substance (p< 0.05).
DISCUSSION
Previously, our group has measured plasma levels of anandamide
and OEA in 29 schizophrenia patients with comorbid SUDs
(cannabis> alcohol> cocaine), before and after 12-week treat-
ment with quetiapine. We found that peripheral levels of anan-
damide and OEA were both increased in dual-diagnosis patients,
relative to controls. Noteworthy, these elevations were not normal-
ized by quetiapine treatment, despite improvements psychiatric
and SUD outcomes (Potvin et al., 2008). In the current study,
plasma anandamide levels were reduced in SUD patients, but nor-
mal in non-abusing schizophrenia patients, and both anandamide
and OEA levels remained reduced in the SUD group after que-
tiapine treatment. Taken together, the results from both studies
(previous and current) highlight a striking opposite phenomenon,
namely that peripheral anandamide and OEA levels are elevated
in dual-diagnosis schizophrenia while both being reduced in non-
psychosis substance abusers. Given that anandamide and OEA
alterations were not normalized during treatment, such results
strongly suggest that ECB alterations are trait markers of SUD.
Our results have shown that the involvement of ECBs in SUDs is
expressed in opposite ways, according to the presence or absence of
a comorbid schizophrenia diagnosis, suggesting a “mirror effect.”
Such a result must be interpreted cautiously. On one hand, given
the role of ECBs in the brain reward system, it is possible that
elevations of anandamide and OEA levels constitute risk factors
leading to SUDs in individuals with psychosis vulnerability. Alter-
natively, it is also possible that anandamide and OEA elevations are
endogenous markers of psychosis vulnerability in the context of
Table 1 | Anandamide and OEA at baseline according to schizophrenia or substance use disorder compared to healthy controls.
Variable HC (n=27) SCZ patients (n=25) SUD patients (n=38) Statistics Multiple comparison*
Anandamide (ng/mL) 1.1 (0.4) 1.1 (0.2)** 0.7 (0.2) F =24.3; p=0.0001 SUD<HC and SCZ
OEA (ng/mL) 1.6 (0.7) 1.3 (0.4)** 1.0 (0.5) F =11.2; p=0.0001 SUD<HC
HC, healthy controls; OEA, oleoylethanolamide; SCZ, schizophrenia; SUD, substance use disorders; *After Bonferroni correction; **n=21, missing data.
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Table 2 | Changes in plasma endocannabinoid levels during quetiapine
treatment.
Variable Baseline LOCF data Statistics
Non-abusing schizophrenia patients (n=15)*
Anandamide (ng/mL) 1.1 (0.3) 1.0 (0.3) F =0.7; p=0.415
Oleoylethanolamide (ng/mL) 1.3 (0.4) 1.3 (0.3) F =0.2; p=0.635
Non-psychosis patients with substance use disorders (n=24)
Anandamide (ng/mL) 0.7 (0.2) 0.7 (0.3) F =0.3; p=0.599
Oleoylethanolamide (ng/mL) 1.0 (0.5) 1.1 (0.6) F =0.5; p=0.508
LOCF, last-observation-carried-forward; *missing data.
substance abuse, more precisely cannabis abuse. Consistently with
this latter interpretation, it has been shown that cannabis smok-
ing can produce psychotomimetic effects, and that it moderately
increases the risk for psychotic symptoms (Arseneault et al., 2004).
To explain the striking“mirror effect”reported here, one poten-
tial explanation may be related to the fact that∆9-THC, the main
psychoactive agent of cannabis, is a partial agonist at CB1 recep-
tors (Pertwee, 2005), and may therefore produce opposing effects
on anandamide and OEA based on a priori psychosis vulnera-
bility. Alternatively, it may produce different psychiatric effects
based on the individual’s basal ECB tone. To explain this “mirror
effect,” it may also be relevant to consider the balance between
dopamine and ECBs in psychosis homeostasis. Using PET, var-
ious studies have shown that amphetamine-induced dopamine
release is increased in schizophrenia, mostly in the acute phase of
illness (Laruelle, 1998; Guillin et al., 2007). On the opposite, the
chronic use of psychoactive substances has been shown to down-
regulate striatal dopaminergic neurotransmission (Volkow et al.,
1993, 1996, 2001; Hietala et al., 1994; Wang et al., 1997; Gino-
vart et al., 1999; Martinez et al., 2004; Lee et al., 2009). Given
that anandamide has been shown to inhibit dopamine release in
the striatum, as a retrograde messenger (Giuffrida et al., 1999),
and that OEA inhibits drug-induced dopamine elevations in the
reward system via PPAR-α (Melis et al., 2008),one may hypothesize
that the inverted endocannabinoid alterations in dual-diagnosis
patients and SUD patients are the results of complex interac-
tions with dopamine. Against this view, however, it is important to
mention that the dopaminergic dysfunctions associated with both
schizophrenia and substance abuse are mostly transient (Laruelle,
1998; Volkow et al., 2001), whereas the endocannabinoid alter-
ations reported here and in our previous study are persistent in
time (Potvin et al., 2008).
One of the research implications of our results is that longitudi-
nal studies would be needed in adolescent substance users, before
they develop schizophrenia or SUD, to understand the involve-
ment of ECBs in SUD – with a particular attention to specific
substances, such as alcohol, cannabis, and stimulants. Our results
may also have future implications for the pharmacological treat-
ment of SUDs, as they suggest that CB1 or PPARs agonists would
be required in substance abusers, whereas CB1 or PPAR antago-
nists would be required in dual-diagnosis schizophrenia patients.
Although CB1 antagonists have shown promise in pre-clinical
models of addiction to various substances (Economidou et al.,
2006; Femenia et al., 2010; Yu et al., 2011), and PPAR-γ agonists
have been shown to reduce alcohol drinking in rodents (Stop-
poni et al., 2011), the clinical efficacy of CB1 antagonists for SUD
remains to be proven (Cahill and Ussher, 2011) and PPAR agonists
have not been tested thus far in humans. The adequate pharma-
cological modulation of ECB tone could also provide therapeutic
targets. One of them is fatty-acid amide hydrolase (FAAH), the
enzyme responsible for the degradation of anandamide and OEA,
which offers a more selective way to alter ECB activity. FAAH
inhibitors seem to be potent modulators of motivation and goal-
directed behaviors associated with SUD (such as cocaine) without
reducing consumption in rat models (Adamczyk et al., 2009).
However, FAAH inhibitors have not been tested thus far for the
treatment of alcohol or drug addiction in humans.
Our study has three main limitations. First, our study was
limited by the inclusion of various psychoactive substances, mak-
ing the attribution of our results to specific substances difficult.
Another limitation of our study is the inclusion in the non-abusing
schizophrenia group having a small number of patients. The lack
of difference in ECB levels between non-abusing schizophrenia
patients and controls could therefore be explained by a type-II
error. Finally, we measured peripheral, not central, levels of anan-
damide, and OEA, and this may have influenced our results. For
instance, the absence of difference in plasma anandamide and
OEA between non-abusing patients with schizophrenia-spectrum
disorders and controls might be explained by various peripheral
influences, especially since ECBs are involved in various systems
(Hohmann and Suplita, 2006; Pacher et al., 2006; Matias and Di
Marzo, 2007; Hiley, 2009). Moreover, the absence of ECB alter-
ations in the schizophrenia group does not preclude central ECB
disturbances. Thus far, two studies have shown that anandamide
levels are elevated in the CSF of schizophrenia patients (Leweke
et al., 1999; Giuffrida et al., 2004) and another one showed that CSF
anandamide levels are also elevated in the prodromal phase of psy-
chosis (Koethe et al., 2009). Importantly, CSF OEA levels were not
altered in these three studies. As for the peripheral measurement
of ECBs in schizophrenia, De Marchi et al. (2003) showed that
blood anandamide levels were elevated in small group (n= 12)
of schizophrenia patients, during the acute phase of illness. In
contrast, the serum levels of both anandamide and OEA were
shown to be unaltered in schizophrenia (Giuffrida et al., 2004)
as well as in the prodromal phase of psychosis (Koethe et al.,
2009).
CONCLUSION
Our study has highlighted a “mirror effect” of comorbid schiz-
ophrenia on peripheral ECB alterations in SUDs. Given the lack
of changes during treatment in ECB levels, our results further
suggest that ECB alterations in SUD are trait-, not state-, depen-
dent. Longitudinal studies are required to investigate the bio-
logical reasons for the inverted pattern of ECB alterations in
substance abusers with and without schizophrenia. The precise
role of specific psychoactive substances on our results will also
need to be determined. Research in this field could significantly
help elucidate the neurobiological dysfunctions underlying the
schizophrenia-substance abuse comorbidity, and it may also open
new therapeutic perspectives in the future.
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